Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

There’s a new drug in the wings to treat Covid, an at-home treatment called molnupiravir. Merck Pharmaceutical’s new “Covid pill” will supposedly be accessible medicine to treat ...

The US has also ordered 3.1 million doses of molnupiravir for around $2.2 billion. Merck – which is developing the drug with Ridgeback Biotherapeutics – is one step ahead for a regulatory ...

The green light means that Paxlovid – based on nirmatrelvir (formerly PF-07321332) and ritonavir – has been cleared for use in the US ahead of rival therapy molnupiravir from Merck & Co and ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

This article was initially published on Wednesday and has been updated on Thursday after the FDA authorized Merck's antiviral pill molnupiravir. Read next ...

Merck said final study results showed molnupiravir reduced hospitalization and death by 30 percent among adults infected with the coronavirus, when compared with adults taking a placebo.

The Food and Drug Administration announcement on Merck's molnupiravir comes one day after the agency cleared a competing drug from Pfizer. Pfizer's pill, Paxlovid, is likely to become the first ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese ...